The Caring Ambassadors Program provides this website to help you and your loved ones
understand your disease and some of the health care options available to you.

Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your health care providers will be in the best possible situation to determine the best treatment approach for you.

Offered for Free the Choices bundle. A trilogy of books with comprehensive lung cancer information.

Lung Cancer Choices 5th Edition can be a useful tool for anyone who is caring for someone with lung cancer, but its primary focus is on the patient. This book is suitable for both the newly diagnosed and those who have been living with lung cancer for some time.

MY CHOICES© is a tool to help you recognize and act upon what you can control in your health care journey to achieve optimal healing, regardless of the illness you face. It contains elements of a guide book, health planner, journal, and activity book to help orient you to and plan for the journey ahead.

Learn More about lung cancer question builder

Weekly News Update. Caring Ambassadors Program provides 3 weekly news updates covering Lung Cancer News, Hepatitis C News, and My Choices© Update. Receive them delivered weekly to your inbox.

Weekly News Update

Lung Cancer News

Week Ending November 28, 2022

FDA approves AstraZeneca’s Imfinzi, Imjudo for metastatic lung cancer
“Using immunotherapy alongside chemotherapy has proved promising in a recent phase 3, multicenter, clinical trial of patients with non-small cell lung cancer that has spread. Following the publication of the trial results, the Food and Drug Administration (FDA) has approved AstraZeneca’s drugs Imfinzi (durvalumab) and Imjudo (tremelimumab) alongside chemotherapy already approved in the U.S. for patients with metastatic non-small cell lung cancer.”

Ultrafine particles can change defense against lung cancer
“While it may seem common knowledge that smoking is bad for your lungs, if and how ultrafine particles present in cigarette smoke impact the development and progression of lung cancer remains unclear. Researchers at Baylor College of Medicine sought to find how airborne ultrafine particles in smoke can change a host’s defense against lung cancer.”

Tumor matrix profiles determine the risk and prognosis of a common type of lung cancer
“Scientists at the Garvan Institute of Medical Research have identified molecular profiles of the surrounding matrix of a common type of lung cancer that might indicate which patients are likely to develop aggressive tumors.”

FDA rejects Spectrum’s lung cancer drug poziotinib
“Spectrum is expected to make an announcement later today, but the CRL has been widely anticipated, given that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 against approval of poziotinib in September, saying that the benefits of poziotinib do not outweigh its risks. Spectrum filed for accelerated approval of poziotinib as a second-line treatment for patients with HER2 exon 20 insertion-mutated, non-small cell lung cancer (NSCLC), but the FDA was unconvinced by the phase 2 data presented in support of the drug.”

Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification
The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of the phase 2 INSIGHT trial (NCT01982955).”

Impact of Loneliness on Functioning in Lung Cancer Patients
“Lung cancer is the leading cause of cancer death and carries a greater degree of stigma. Lung cancer stigma contributes to social isolation and increases loneliness, which has an impact on quality of life, increases depressive symptoms and hence affects all aspects of functioning. Functioning is assessed in five dimensions (physical, psychological, cognitive, social and life roles). The aim of the study was to assess the impact of loneliness on the functioning, nutritional status and quality of life of patients with lung cancer.”

Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
“SHANGHAI and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ — Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing first-in-class and best-in-class biotherapeutics for cancer, announced today an open label, phase 2, multicenter, randomized trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC).”


My Choices© Update

Week Ending November 28, 2022

Exercising between 8–11 am may be best for cardiovascular health
“Although exercise is always generally good for health, a large new prospective study finds that one particular time of day may offer the greatest benefit when it comes to lowering the risk of cardiovascular disease (CVD) and stroke. The study found that physical activity in the morning, between 8 and 11 a.m., had the greatest positive effect on a person’s risk of CVD and stroke compared to activity at other times of day.”

Exercise can reduce severity of breast cancer treatment side effects
“Radiotherapy has emerged as an important component of breast cancer treatment but can lead to cancer-related fatigue and negatively impact patients’ health-related quality of life. Research has revealed exercise may make the treatment more tolerable for patients.”

Homeopathic Add-On Improves QOL, Survival in Non-Small Cell Lung Cancer
“Researchers in Austria found that quality of life (QOL) was improved with the use of an individualized homeopathic regimen over placebo in patients with stage IIIB/IIIC or IV non-small cell lung cancer (NSCLC). They also reported a longer median survival time among patients who received the intervention. The study investigators reported their findings in the journal The Oncologist.”

This Standing Workout Hits Every Muscle Group And Counteracts The Effects Of Sitting
“It only takes 16 minutes.”

Acupuncture Might Ease Back Pain During Pregnancy
“THURSDAY, Nov. 24, 2022 (HealthDay News) — Many women experience back pain during pregnancy and a new study review suggests an ancient treatment can help.”

Help Open People’s Eyes.

Would you be so kind as to share a snippet about your lung cancer experience with us?

There is no right way to share – talk, write, draw, speak poetry – just please SHARE. Email us: